HAVN Life Sciences Inc Ordinary Shares HAVLF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.03
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.01–0.15
- Bid/Ask
- $0.00 / $6,800.11
- Market Cap
- $148,859.97
- Volume/Avg
- 391 / 4,367
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
HAVN Life Sciences Inc is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind. Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, it offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 6
- Website
- https://www.havnlife.com
Valuation
|
Metric
|
HAVLF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HAVLF
|
|---|---|
Quick Ratio | 0.60 |
Current Ratio | 2.68 |
Interest Coverage | −1,030.99 |
Quick Ratio
HAVLF
Profitability
|
Metric
|
HAVLF
|
|---|---|
Return on Assets (Normalized) | −102.81% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −116.98% |
Return on Assets
HAVLF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Vbsyqwds | Jbjgbh | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Chtwdjs | Cfdcjj | $114.2 Bil | |||
| Moderna Inc
MRNA
| Pflysqg | Mjmb | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Gnwgkvnk | Wddzj | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Mpbkcwr | Hskq | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dgrgpmcf | Svvnhqm | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Sbytqxxw | Gfkhfbd | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Tqdpddlnq | Lfx | $12.8 Bil | |||
| Incyte Corp
INCY
| Wrgzswv | Qvzbp | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Chddydmhx | Kylgjtp | $12.2 Bil |